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Prognostic indicators in Cerebral Venous Sinus Thrombosis
Bilal Hameed, Nadir Ali Syed
Department of Medicine, The Aga Khan University, Karachi.
Abstract
Cerebral venous sinus thrombosis (CVT) can affect
all age groups, particularly women of childbearing age.
Overall prognosis for survival and functional independence
is better than it was believed. Mortality usually ranges from
6-15% and transtentorial herniation is the major cause of
death. Approximately 80% of patients are functionally inde-
pendent in the long term. Altered mental status and cerebral
haemorrhage at presentation are the strongest predictors of
death and disability. Patients with CVT related to pregnan-
cy and puerperium generally do better than patients with
other causes. Septic CVT carries a worse prognosis than
aseptic CVT and of the latter, patients with syndrome of iso-
lated intracranial hypertension have a better prognosis than
those with focal deficits or encephalopathy. Anticoagulation
is believed to improve outcome in CVT although robust
data are lacking. Epilepsy, headaches, visual loss, pyrami-
dal deficits and cognitive impairment are some of the long
term sequelae. The risk of recurrence of CVT is low, partic-
ularly after the first 12 months of the first episode.  
Introduction
CVT is a cerebrovascular disorder that can affect all
age groups.1 Although CVT causes stroke far less frequent-
ly than arterial pathologies2,3, it has a predilection for
younger individuals, particularly women of childbearing
age.4 Four main clinical patterns of CVT are generally rec-
ognizeed and these include presentation with focal neuro-
logical deficits and/or seizures, isolated intracranial hyper-
tension, subacute diffuse encephalopathy and painful oph-
thalmoplegia and the distinction of patients into these clini-
cal patterns carries prognostic implication.5,6
Earlier reports of CVT, in the first half of the 20th
century, were usually based on autopsy findings and CVT
was generally considered to be a fatal disease.7 Diaz et al
reviewed 203 cases of CVT reported between 1942 and
1990 and found an overall mortality of 49.3%.8 An Austrian
retrospective study of 42 cases showed a mortality as low as
2%9 while a Mexican study reported a comparatively high-
er figure of about 23%.10 In other series reported since
1980's, however, the mortality rates have been consistently
found to be between 6 and 15% in reports emerging from
different parts of the world.11-13 The mortality rate was 8%
in a French study, 6% in a German study and 8% in an
Italian study.14-16 In the largest reported prospective series
of 624 patients by the International Study on Cerebral Vein
and Dural Sinus Thrombosis (ISCVT) the mortality was
8.3%. In this study, a significant majority (92%) of deaths
attributable to CVT occurred within 30 days of symptom
onset17, a finding that is shared by other series as well.18,19
The main cause of death occurring within the first
few days of presentation of CVT is transtentorial herniation
due to a focal lesion, multiple lesions or diffuse oedema
while causes of death over the next few weeks include
transtentorial herniation, uncontrolled seizures, sepsis, pul-
monary embolism, underlying infection or malignan-
cy.4,16,17
The extent of functional recovery in survivors of
CVT is better as compared to patients with arterial throm-
bosis in which the proportion of permanent dependent
patients ranges between one third and two third of sur-
vivors20 which is in contrast to CVT in which an independ-
ent survival of around 80% is commonly found. Of 59
patients in the study by Cerebral Venous Sinus Thrombosis
Study group, conducted in Netherlands and United
Kingdom, 83% of the patients had independent survival
(Oxford handicap score =2) while 17% of patients had poor
outcome, defined as death or dependency (Oxford handicap
score =3) at 12 weeks.5 Eighty two percent of 91 prospec-
tive cases of Portuguese cohort of VENOPORT study had
complete recovery at 1 year.18 Of  79 patients, collected
both retrospectively and prospectively, over a period of
about 16 years by a German group, 73% had excellent
recovery with modified Rankin score (mRS) of 0-1, 4% had
partial recovery with mRS of 2, 8% had significant disabil-
ity with mRS of 3-5 while 15% died at 6 months.15 After a
median follow-up of 16 months in ISCVT, 79% made com-
plete recovery (mRS 0-1), 8% made partial recovery though
they were independent (mRS 2), 5% were dependent (mRS
3-5) while 8% had died (mRS 6).3 In a French cohort of 55
patients, 82% of patients were independent (mRS 0-2)
while 18% were dependent or dead (mRS 3-6) at 3 years.14
Altered mental status and cerebral haemorrhage at
presentation have been found to be the most consistent and
strongest predictors of death and disability.3,5,13 Older age
(>37 years in ISCVT), male sex, seizures at admission,
rapid evolution of thrombosis, the presence of focal deficits
and CNS infection and cancer as the underlying cause also
predict poor outcome.3,15,21 Although the site of thrombosis
has not been found to correlate with the outcome in certain
studies5,16, ISCVT found involvement of cortical veins,
deep cerebral veins and superior sagittal sinus, intracerebral
haemorrhage on right side, posterior fossa lesions and
parenchymal lesions especially ones >5 cm in their larger
diameter to be poor prognostic factors.17 Patients who dete-
riorate during hospital stay in terms of their encephalopathy
or focal neurological deficits or those who either develop
new focal deficits or new lesions on neuroimaging (infarc-
tion, haemorrhage or oedema) are more likely to die than
those without these findings.17 The VENOPORT study
identified anticoagulation, absence of aphasia, age <45
years, no encephalopathy at admission and no worsening
after admission as predictors of good outcome.13,18
Intracranial circulation time (ICT) and the degree of
recanalization have also been proposed as possible prognos-
tic markers in CVT.21,22 ICT is defined as the time from the
first appearance of the contrast agent in the arterial system
to the complete clearing from the venous system on cerebral
angiography and has a normal value of <9 seconds. In a
German series in which patients were treated with dose-
adjusted intravenous heparin, a markedly delayed ICT
(mean 21.2 s) was more frequently found in patients who
died than in survivors (mean ICT 13.3 s).21 Strupp et al
showed after a long-term follow-up of 40 patients using
MRI and MRA that although the prevalence of persisting
neurological deficits did not differ between patients with
complete or partial recanalization, patients with no recanal-
ization had significantly more neurological sequelae.22
Some investigators have identified presence of empty delta
sign on CT scan as a predictor of poor outcome.11
The prognosis of CVT related to pregnancy and
puerperium is considered to be better compared to CVT
related to other causes. Cantu et al compared 67 patients of
obstetric CVT with 46 patients of nonobstetric CVT and
found that although the initial severity of illness was similar
in both groups with comparable neurological and neuroradi-
ological findings, the final outcome was good in 80% of the
former group and 58% of the latter group with significant
difference in mortality as well which was 9% in patients
with pregnancy-related CVT and 33% in patients with other
causes23, others have also noted similar findings.4,15
The prognosis of septic CVT is worse than nonsep-
tic CVT with a reported mortality of 30% and 78% in cav-
ernous and superior saggital sinus thromboses respective-
ly.24 Although no convincing data exist, anticoagulation
(AC) may improve prognosis by reducing morbidity and
mortality in septic CVT and is generally considered a part
of treatment in addition to antibiotics.2,25
Amongst patients with aseptic CVT, patients who
present with syndrome of isolated intracranial hypertension
(IIH) have a better prognosis compared with those who
present with focal deficits or encephalopathy. In Preter et
al's series of 77 patients, 11 patients were left with perma-
nent neurologic sequelae and only 2 of them had initially
presented with IIH.26 In ISCVT, patients presenting with
IIH had a better outcome (7% dead/dependent) than the
remaining patients (13.6% dead/dependent) after a follow-
up of median of 16 months.3 Others have had similar
results8 and IIH has been identified as a marker of good out-
come.5,14
ISCVT investigators have reported that the progno-
sis of elderly patients with CVT is worse than that of
younger patients. In ISCVT at the end of follow-up of medi-
an of 16 months, only 49% of elderly patients (= 65 years)
made a complete recovery (versus 82% in younger
patients), whereas 27% died and 22% were dependent (ver-
sus 7 and 2% respectively in younger patients).27
An Italian retrospective study of 48 patients reported
that the outcome of CVT patients from non-selected first-
referral centres was similar to that from specialized cen-
tres.16 ISCVT which recruited patients from 5 continents
found no significant difference in outcome between patients
enrolled in different countries or world regions.3
Barinagarrementeria et al proposed a prognostic scale
based on clinical, computed tomography (CT) and cere-
brospinal fluid (CSF) analysis. The presence of coma or bilat-
eral pyramidal signs was rated at 3, that of generalized
seizures at 2 and that of meningeal signs, bilateral lesions on
CT scan and haemorrhagic CSF all at 2. The prognosis was
found to be 100% good when total score was <3, usually good
(85%) with a score of 4-5, usually bad (90%) with a score of
6-8 and 100% bad with a score of >9.10 The scale, however,
has not been consistently validated in various series of CVT. 
It is generally recognized that although several pre-
dictors of good and bad outcome have been identified in
patients with CVT, the prognosis of a given individual
patient remains variable and highly unpredictable.28
Whether AC improves outcome in CVT remains
uncertain. Following initial reports of benefit of heparin in
CVT, AC was used in many patients and encouraging
results were reported in various series.9 A trend towards
benefit in patients treated with AC was noted in three
prospective randomized trials comparing the efficacy of
heparin vs. placebo in CVT.19,29,30 In the German trial of
dose-adjusted intravenous heparin vs. placebo in 22
patients, 8 patients recovered fully and none died in the
heparin-arm while 1 patient recovered fully and 3 died in
the placebo-arm.29 In the British-Dutch trial of 60 patients
with CVT, low molecular weight heparin was compared
with placebo. A poor outcome was noted in 6 of 30 patients
(20%) at 3 weeks and in 3 patients (10%) at 12 weeks in the
heparin group as compared to 7 of 29 patients (24%) at 3
weeks and 6 patients (21%) at 12 weeks in the placebo
group.19 A meta-analysis of these two trials showed that the
use of AC led to an absolute risk reduction in mortality of
14% and in death or dependency of 15% with relative risk
reductions of 70% and 56% respectively.19 The third trial
compared intravenous unfractionated heparin with placebo
in 57 patients with puerperal CVT and found a nonsignifi-
cant improvement in patients treated with AC.36 The data,
though not statistically significant, are generally considered
to be clinically meaningful and AC is believed to improve
prognosis in CVT.2,31
552 J Pak Med Assoc
Few studies have looked at the long-term outcome in
patients with CVT. One of the common sequelae in these
patients is epileptic seizures. These almost always occur in
those patients who had seizures during the acute stage of the
disease and a rate of 5-16% has been reported in various
studies.14,32,33 Occurrence of >2 seizures despite antiepilep-
tic treatment during initial hospitalization has been found to
increase the risk of subsequent epilepsy while the presence
of venous infarct possibly increases the risk.15 Headaches of
variable types and intensities are another long-term problem
affecting the quality of life in these patients and have been
reported to occur in 11-60% of these patients in various
studies, the wide difference likely to be attributable to dif-
ferent ascertainment criteria.3,18,32 Motor deficits (in about
10%), visual loss or visual field defects (in 0.6-10%) and
development of leptomeningeal fistula (in about 3%) have
also been reported.15,18,32 Studies using various neuropsy-
chological batteries aimed at assessing long-term cognitive
outcome have reported cognitive impairment in approxi-
mately 35% of the patients in different cohorts usually in the
form of non-fluent aphasia, working memory deficits and
depression.32,34 Anticoagulation has not been shown to alter
the long-term cognitive outcome.34 The available data also
suggest that although functional disability is uncommon
amongst survivors, many of them (40% in the series report-
ed by cerebral venous thrombosis study group)  are not able
to resume all prior activities or enjoy a previous level of
social and occupational functioning.34
The risk of recurrence of thrombosis, cerebral as
well as extracerebral, appears to be low particularly after the
first 12 months. Of Ameri's original series of 110 patients,
Preter et al followed 77 patients for a median of 63 months
and found recurrence of CVT in 9 patients (12%) in 8 of
whom the recurrence occurred within 12 months of the first
episode. Eleven patients (14.3%) had thrombotic events
other than CVT.26 In Einhaupl's series with a mean follow-
up of 10 years, recurrence of CVT was noted in 5 patients
(6%) out of whom 4 had a relapse in the first 19 months
(mean latency of 10.3 months).2 ISCVT investigators
reported recurrence of CVT in 2.2% and of other thrombot-
ic events in 4.3% after a median follow-up of 16 months.3
In a German series in which 58 patients were followed up
for a median of 31 months, 2 patients (3%) developed recur-
rent CVT and 5 patients (9%) had extracerebral venous
thrombosis.15 Recurrence of CVT occurred in only 1 of 34
patients in an Italian series (median follow-up of 3.5
years)32 and in none of 55 patients in a French series (medi-
an follow-up of 3 years).14 The VENOPORT study reported
a recurrence of CVT in 2% of patients.18
The risk of recurrence of CVT during pregnancy and
puerperium in women who previously suffered from CVT also
seems to be low, again at least after the first 12 months.
Mehraein et al, from their own series and those of others, found
reports of 63 pregnancies with no recurrence of CVT including
21 women whose initial episode was related to pregnancy or
puerperium41. In their own series of 22 pregnancies in 14
women, the mean interval from CVT to subsequent pregnancy
was more than 2 years and this interval might have contributed
to lack of recurrence as relapses of CVT are more likely to
occur in the first 12 months.35 In ISCVT, over a median follow-
up of 16 months, 34 women became pregnant after CVT.
Recurrence of CVT was noted in 1 patient while extracerebral
venous thrombosis occurred in 2 patients.3
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